Oppenheimer Maintains Outperform on Evolent Health, Lowers Price Target to $6
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Oppenheimer analyst Michael Wiederhorn maintains Evolent Health (NYSE:EVH) with a Outperform and lowers the price target from $12 to $6.
Oppenheimer analyst Michael Wiederhorn maintains Evolent Health (NYSE:EVH) with a Outperform and lowers the price target from $12 to $6.